Fmoc-Amino Acid Building Block Synthesis for Solid-Phase Peptide Drug Substance Production

Production of Fmoc-protected α-amino acids for Fmoc-SPPS uses Fluorenylmethoxycarbonyl Chloride (Fmoc-Cl, CAS 28920-43-6) as the electrophilic acylation reagent. The reaction is a Schotten-Baumann process conducted in a mixed dioxane/water system; the free amino acid is dissolved in water and adjusted to pH 8.5–10.5 with sodium carbonate or sodium bicarbonate, while Fmoc-Cl is added as a dioxane solution at a controlled feed rate. The addition ratio is maintained at 1.0–1.2 mol Fmoc-Cl per 1 mol of amino acid, with a reaction temperature window of 0–25 °C and a residence time of 2–12 h. The process is sensitive to pH overshoot: above pH 10.5, Fmoc-Cl hydrolysis to Fmoc-OH accelerates, and the resulting 9-fluorenylmethanol can appear as a crystalline contaminant in reactor pH ports and bottom drain valves. In glass-lined reactors of 2,000–6,000 L, the dioxane solution is introduced below the liquid surface through a dip pipe to limit local reagent accumulation. After acylation, the mixture is acidified to pH 2.0–3.0 with 3 M hydrochloric acid, extracted into ethyl acetate, washed with 5% w/v sodium chloride solution, dried over anhydrous magnesium sulfate, and crystallized from ethyl acetate/n-heptane at -10–4 °C. Residual free amino acid is controlled below 0.1% by HPLC, and residual Fmoc-OH is controlled below 0.5% w/w in the final dry powder. Residual 1,4-dioxane is held under the ICH Q3C(R8) Class 2 limit of 380 ppm where the building block enters a drug substance route. Production is conducted under ICH Q7 chapter 18 for APIs manufactured by chemical synthesis, with written production and process-control records under 21 CFR 211.100. Peptide drug substance purity expectations follow Ph. Eur. monograph 2034 for synthetic peptides. Typical terminal products include Fmoc-Arg(Pbf)-OH, Fmoc-His(Trt)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Thr(tBu)-OH, and Fmoc-Trp(Boc)-OH, which are subsequently used in solid-phase synthesis of GLP-1 receptor agonists, glucagon analogues, and somatostatin receptor ligands. Fmoc-Cl is not suitable for protecting tertiary amines or amide nitrogen; alternative reagents are required for those substrates. The reagent is stored at 2–8 °C under inert gas and must be allowed to reach ambient temperature before opening to avoid condensation-related hydrolysis.

How Are Preloaded Fmoc-Amino Acid Resins Produced Without Substitution Drift?

Preloaded Fmoc-amino acid Wang and 2-chlorotrityl resins are produced by first preparing the Fmoc-amino acid with Fmoc-Cl at 1.0–1.2 mol Fmoc-Cl per 1 mol of α-amine, then anchoring the protected monomer to a functionalized resin support. For Wang resin, the Fmoc-amino acid is activated with 2.0–3.0 equiv diisopropylcarbodiimide and 0.1 equiv dimethylaminopyridine in DMF/DCM at 0–25 °C for 4–12 h. For 2-chlorotrityl chloride resin, the Fmoc-amino acid is coupled at 1.5–4.0 equiv with 2.0–6.0 equiv N,N-diisopropylethylamine in dry dichloromethane at 25 °C for 2–6 h. Residual trityl chloride groups are capped with methanol/pyridine (8:1:1 v/v), and unreacted hydroxyl or amine sites are end-capped with acetic anhydride/pyridine/DMF (1:1:2 v/v) for 30 min. Substitution targets are 0.3–0.8 mmol/g. Substitution is measured by Fmoc release with 20% v/v piperidine/DMF; the dibenzofulvene-piperidine adduct is quantified at 301 nm using ε = 8100 L·mol⁻¹·cm⁻¹. Moisture ingress above 100 ppm in DMF during loading is a primary cause of batch-to-batch substitution drift. In 10–50 L rotary reactors, mixing above 50 rpm has been associated with bead breakage in early process optimization runs, generating fines that lodge in fritted glass filters and slow downstream resin washing. Finished resins are dried under vacuum, packaged under argon, and stored at 2–8 °C. Compliance anchors include ICH Q7 for in-process control, ISO 9001:2015 clause 8.5.2 for identification and traceability, and USP 661 for packaging system leachables assessment. Terminal product types include Fmoc-Arg(Pbf)-Wang resin, Fmoc-Ser(tBu)-2-CTC resin, and Fmoc-Gly-Wang resin used in linear, branched, and cyclic peptide API manufacture.

In solution-phase manufacture of short peptide fragments for generic synthetic peptide APIs, Fmoc-Cl is used for N-terminal protection of amino acids and peptide esters before activation and coupling. The addition ratio is 1.05–1.3 mol Fmoc-Cl per 1 mol of free amine in THF/water or acetone/water with sodium bicarbonate at pH 8.0–9.5 and 0–20 °C for 1–4 h. The protected amino acids are activated with TBTU or EDC/HOAt in DMF and coupled in stepwise or fragment condensation sequences; selective Fmoc removal uses 10–20% v/v piperidine/DMF for 5–20 min. This route is used for desmopressin and oxytocin analogue fragments where solution-phase fragment condensation reduces deletion sequences and racemization observed in some solid-phase routes. Residual Fmoc-Cl is quenched with 1 M glycine, and the resulting Fmoc-glycine adduct is removed by ethyl acetate extraction. Fmoc-Cl is incompatible with free primary and secondary amines before the intended protection step; water content in activation solvents is held below 5% v/v to avoid premature reagent loss. Compliance for this track includes ICH Q3C(R8) for residual solvents, 21 CFR 210.3 and 211.100 for process definition and batch records, Ph. Eur. monograph 2034 for synthetic peptide monographs, and ISO 9001:2015 clause 8.5.4 for preservation of process outputs. Terminal product types are solution-phase peptide APIs and registered generic peptide fragments.

When Fmoc-Cl Is Used as a Pre-Column Derivatizing Agent in Clinical Amino Acid Analysis

Fmoc-Cl has an established use in pre-column derivatization of amino acids for reversed-phase HPLC with fluorescence detection in clinical amino acid profiling. The reagent reacts rapidly with primary and secondary amines in mildly alkaline borate buffer. A typical protocol uses Fmoc-Cl at 10–15 mmol/L in acetonitrile, sample amino acid concentration at 0.1–1.0 mmol/L, and 0.8 mol/L sodium borate buffer at pH 7.7. The reaction proceeds at 20–25 °C for 45–60 s and is quenched with 0.1 mol/L glycine. Excess reagent and hydrolyzed Fmoc-OH are removed by pentane extraction at 1:1 v/v before injection. Separation is performed on a 150 mm × 4.6 mm, 5 µm C18 column with fluorescence detection; quantitation is based on external calibration against Fmoc-amino acid reference standards. This downstream track supplies amino acid reference materials, inborn error of metabolism screening kits, and cell culture media amino acid quality-control panels. Method validation follows ICH Q2(R1) for analytical procedures, and testing laboratories operate under ISO/IEC 17025:2017 clause 7.3 for sampling and method validation. The operational boundary is the limited stability of Fmoc-Cl in aqueous mobile phases: derivatization solutions are prepared fresh daily and stored in amber vials at 2–8 °C to prevent reagent degradation. Terminal product types are clinical diagnostic kits, pharmacopeial amino acid reference standards, and QC panels used in biopharmaceutical media analysis.

For primary cell culture and wound-contacting hydrogel production, Fmoc-protected aromatic gelators are synthesized from Fmoc-Cl and amino acids or dipeptides. The addition ratio is 1.1–1.5 mol Fmoc-Cl per 1 mol of amino group for Fmoc-phenylalanine, Fmoc-tyrosine, and Fmoc-diphenylalanine synthesis, with reaction time 12–24 h at 20–25 °C under nitrogen in anhydrous dichloromethane or aqueous carbonate. After workup and freeze-drying, hydrogel assembly is triggered by a pH switch from 10.5 to 7.0 or by solvent dilution from DMSO into water; critical gelation concentration ranges from 0.1–2.0 wt%. Rheological characterization with a cone-and-plate rheometer records storage modulus G′ between 10²–10⁴ Pa and tan δ below 0.2 within the linear viscoelastic region. Residual DMSO is controlled because elevated residual solvent levels alter gel fibril morphology and reduce primary cell attachment. Published data for terminally sterilized Fmoc-diphenylalanine hydrogels in wound-contact configurations is limited; biocompatibility evaluation therefore follows ISO 10993-5:2009 for in vitro cytotoxicity and ISO 10993-10:2010 for irritation and skin sensitization, with quality system control under ISO 13485:2016 clause 7.5.2. Terminal product types are primary cell culture scaffolds, wound-dressing hydrogels, and local drug delivery depots for research and clinical evaluation.

Automated SPPS platforms demand residual Fmoc-OH below 0.1% w/w in peptide precursors for radiopharmaceutical use

Automated solid-phase synthesizers used for radiopharmaceutical peptide precursor assembly rely on Fmoc-Cl-derived amino acids rather than direct Fmoc-Cl addition. Fmoc-Cl is consumed upstream at 1.0–1.2 mol per 1 mol of amino acid to prepare the protected monomers. During automated SPPS, Fmoc-amino acids are coupled at 3.0–5.0 equiv relative to resin active sites using HATU/DIPEA activation in DMF at 50 °C. Deprotection uses 20% v/v piperidine/DMF, and cleavage from 2-chlorotrityl or Wang resin is performed with TFA/triisopropylsilane/water at 95:2.5:2.5 v/v/v. Crude peptides are purified by preparative reversed-phase HPLC and lyophilized. Residual Fmoc-OH in the final peptide precursor is controlled below 0.1% w/w because hydrophobic Fmoc-derived impurities can co-elute with protected peptide intermediates and alter radiolabelling efficiency. Compliance for this track includes ICH Q7 for chemical synthesis and USP 823 for positron emission tomography drug preparation and research use. Terminal product types include somatostatin analogue and PSMA-targeting peptide precursors intended for 68Ga and 177Lu radiolabelling in diagnostic imaging or radiotherapeutic development.